What this evidence supports
VITAL-H is designed to test whether repurposed drugs can improve aging-related outcomes within a regulatory pathway.
What it does not establish
The trial is prospective and does not establish benefit before results are available.
Record details
- Source authority
- ARPA-H
- Evidence level
- E5
- Directness
- 5/5
- Recency
- 4/5
- Decision relevance
- 5/5
- Date
- 2026-02-24
Primary source
Related intelligence
PROSPR VITAL-H will test repurposed drugs in a phase 3 hybrid aging trial